Skip to main content
eScholarship
Open Access Publications from the University of California

UCSF

UC San Francisco Previously Published Works bannerUCSF

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.

  • Author(s): Collisson, Eric A
  • Sadanandam, Anguraj
  • Olson, Peter
  • Gibb, William J
  • Truitt, Morgan
  • Gu, Shenda
  • Cooc, Janine
  • Weinkle, Jennifer
  • Kim, Grace E
  • Jakkula, Lakshmi
  • Feiler, Heidi S
  • Ko, Andrew H
  • Olshen, Adam B
  • Danenberg, Kathleen L
  • Tempero, Margaret A
  • Spellman, Paul T
  • Hanahan, Douglas
  • Gray, Joe W
  • et al.

Published Web Location

https://doi.org/10.1038/nm.2344
Abstract

Pancreatic ductal adenocarcinoma (PDA) is a lethal disease. Overall survival is typically 6 months from diagnosis. Numerous phase 3 trials of agents effective in other malignancies have failed to benefit unselected PDA populations, although patients do occasionally respond. Studies in other solid tumors have shown that heterogeneity in response is determined, in part, by molecular differences between tumors. Furthermore, treatment outcomes are improved by targeting drugs to tumor subtypes in which they are selectively effective, with breast and lung cancers providing recent examples. Identification of PDA molecular subtypes has been frustrated by a paucity of tumor specimens available for study. We have overcome this problem by combined analysis of transcriptional profiles of primary PDA samples from several studies, along with human and mouse PDA cell lines. We define three PDA subtypes: classical, quasimesenchymal and exocrine-like, and we present evidence for clinical outcome and therapeutic response differences between them. We further define gene signatures for these subtypes that may have utility in stratifying patients for treatment and present preclinical model systems that may be used to identify new subtype specific therapies.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
Current View